Which Factors Impact DLBCL Treatment Decisions?
Link to Full Transcript: https://bit.ly/3FASqoS
When making a decision about diffuse large B-cell lymphoma (DLBCL) treatment, what should you consider? Dr. Justin Kline reviews key patient factors that impact therapy decisions, including comorbidities and treatment side effects.
Dr. Justin Kline is the Director of the Lymphoma Program at the University of Chicago Medicine. Learn more about Dr. Kline: https://www.uchicagomedicine.org/find-a-physician/physician/justin-kline.
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome. Subscribe now to receive the latest news on cancer treatment and research: https://powerfulpatients.org/connect
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information.
Keywords: Dr. Justin Kline,University of Chicago Medicine,diffuse large B-cell lymphoma,DLBCL,non-Hodgkin lymphoma,NHL,B-cell NHL,aggressive NHL,B-lymphocytes,lymphocytes,white blood cell,lymph nodes,T cells,antibody,rituximab,Rituxan,radiation therapy,remission,R-CHOP,cyclophosphamide,Cytoxan,Oncovin,prednisone,chemotherapy,doxorubicin hydrochloride,vincristine sulfate,DLBCL symptoms,treatment decisions,treatment side effects,DLBCL treatment